Walleye Partners LLC Takes Position in Harrow, Inc. $HROW

Walleye Partners LLC purchased a new position in Harrow, Inc. (NASDAQ:HROW) during the fourth quarter, Holdings Channel.com reports. The firm purchased 13,477 shares of the company’s stock, valued at approximately $660,000. Harrow comprises about 0.7% of Walleye Partners LLC’s investment portfolio, making the stock its 21st biggest position.

Several other hedge funds and other institutional investors have also modified their holdings of HROW. Blackhawk Capital Partners LLC purchased a new position in Harrow in the third quarter valued at about $5,272,000. Penn Capital Management Company LLC purchased a new stake in shares of Harrow during the 3rd quarter worth about $15,717,000. Brookstone Capital Management lifted its holdings in shares of Harrow by 232.5% during the 3rd quarter. Brookstone Capital Management now owns 45,775 shares of the company’s stock valued at $2,205,000 after buying an additional 32,009 shares during the last quarter. Calamos Advisors LLC acquired a new stake in shares of Harrow during the 3rd quarter valued at about $1,088,000. Finally, LJI Wealth Management LLC bought a new stake in shares of Harrow in the 3rd quarter valued at approximately $1,445,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Down 2.6%

Shares of HROW stock opened at $39.45 on Wednesday. The stock’s 50 day simple moving average is $40.40 and its 200 day simple moving average is $42.43. Harrow, Inc. has a twelve month low of $21.12 and a twelve month high of $54.85. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -232.05 and a beta of 0.31.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HROW shares. Cantor Fitzgerald dropped their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. B. Riley Financial reissued a “buy” rating and issued a $65.00 target price (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Zacks Research upgraded shares of Harrow from a “strong sell” rating to a “hold” rating in a research note on Friday, April 3rd. William Blair restated an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Harrow in a report on Thursday, March 19th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Harrow has a consensus rating of “Moderate Buy” and an average price target of $69.86.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.